Stockreport

Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package? [Yahoo! Finance]

iTeos Therapeutics, Inc.  (ITOS) 
PDF Total compensation is 38% above industry average iTeos Therapeutics' three-year loss to shareholders was 17% while its EPS was down 40% over the past three years Sh [Read more]